TILT Biotherapeutics
PrivateLast Round
Series B
May 13, 2025
Total Funding Raised
$66.6M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
TILT Biotherapeutics is a biotechnology company developing oncolytic immunotherapies to enable T-cell therapies for solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TILT Biotherapeutics Comparables
Compare TILT Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Accession Therapeutics Limited | 88% | |
| Akamis Bio | 85% | |
| ORCA Therapeutics | 85% |
TILT Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 13, 2025 | ||||
| Series A | Feb 7, 2023 | ||||
| Grant | Feb 7, 2023 | ||||
| Series A | Jun 14, 2022 | ||||
| VC Round | Jun 16, 2020 | ||||
Seed | Dec 16, 2016 |
TILT Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series B, Series A |
| Tesi | Series B, Series A |
| Business Finland | VC Round |
| Lifeline Ventures | Series B, Seed, Series A |
| EIC Accelerator | Grant |
| Tekes | Seed |
| Stephen Industries Inc Oy | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
Grew 15% QoQ, from 26 to 30 employees.
- Apr 19, 2026
Monthly visitors increased 252% MoM.
TILT Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TILT Biotherapeutics's valuation, stock price, and market status.
Is TILT Biotherapeutics a public or private company?
TILT Biotherapeutics is a private company.
What is the current stock price of TILT Biotherapeutics?
TILT Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks TILT Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TILT Biotherapeutics worth (valuation)?
Valuation information for TILT Biotherapeutics is not publicly available.
Can I buy TILT Biotherapeutics stock?
TILT Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TILT Biotherapeutics's last funding round?
TILT Biotherapeutics's most recent funding round was Series B on May 13, 2025.
Who are the main investors in TILT Biotherapeutics?
Key investors in TILT Biotherapeutics include Lifeline Ventures.
Will TILT Biotherapeutics IPO soon?
No public IPO plans have been announced for TILT Biotherapeutics.
How can I track TILT Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in TILT Biotherapeutics's shares on secondary markets.